Clonidine treatment of the opiate withdrawal syndrome. A review of clinical trials of a theory.
D000320:Adrenergic Fibers / Q000502:physiology; D000818:Animals; D000929:Antidepressive Agents, Tricyclic / Q000009:adverse effects; D001921:Brain / Q000503:physiopathology; D002986:Clinical Trials as Topic; D003000:Clonidine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use*; D011431:Dextropropoxyphene / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006556:Heroin Dependence / Q000534:rehabilitation; D006801:Humans; D008125:Locus Coeruleus / Q000503:physiopathology; D008691:Methadone / Q000009:adverse effects / Q000627:therapeutic use; D009020:Morphine / Q000009:adverse effects; D009271:Naltrexone / Q000008:administration & dosage; D009294:Narcotics / Q000009:adverse effects*; D009638:Norepinephrine / Q000502:physiology; D051381:Rats; D013375:Substance Withdrawal Syndrome / Q000188:drug therapy* / Q000503:physiopathology
D000929:Antidepressive Agents, Tricyclic; D009294:Narcotics; D009271:Naltrexone; D009020:Morphine; D003000:Clonidine; D011431:Dextropropoxyphene; D008691:Methadone; C025655:lofexidine; D009638:Norepinephrine